Naringin is a major and selective clinical inhibitor of organic anion-transporting polypeptide 1A2 (OATP1A2) in grapefruit juice

被引:234
作者
Bailey, D. G. [1 ]
Dresser, G. K.
Leake, B. F.
Kim, R. B.
机构
[1] Univ Western Ontario, Lawson Hlth Res Inst, London Hlth Sci Ctr, London, ON, Canada
[2] Univ Western Ontario, Dept Med, London, ON, Canada
[3] Univ Western Ontario, Dept Physiol & Pharmacol, London, ON, Canada
[4] Vanderbilt Univ, Sch Med, Dept Clin Pharmacol, Nashville, TN 37212 USA
关键词
D O I
10.1038/sj.clpt.6100104
中图分类号
R9 [药学];
学科分类号
1007 ;
摘要
We showed previously that grapefruit and orange juices inhibited human enteric organic anion-transporting polypeptide (OATP) 1A2 in vitro and lowered oral fexofenadine bioavailability clinically. Inhibition of OATP1A2 transport by flavonoids in grapefruit (naringin) and orange (hesperidin) was conducted in vitro. Two randomized, crossover, pharmacokinetic studies were performed clinically. In one study, 120 mg of fexofenadine was ingested with 300 ml grapefruit juice, an aqueous solution of naringin at the same juice concentration (1,200 mu M), or water. In the other study, fexofenadine was administered with grapefruit juice, with or 2 h before aqueous suspension of the particulate fraction of juice containing known clinical inhibitors of enteric CYP3A4, but relatively low naringin concentration ( 34 mu M), or with water. Naringin and hesperidin's half-maximal inhibitions were 3.6 and 2.7 mu M, respectively. Fexofenadine area under the plasma drug concentration-time curves (AUCs) with grapefruit juice and naringin solution were 55% (P < 0.001) and 75% (P < 0.05) of that with water, respectively. Fexofenadine AUCs with grapefruit juice and particulate fractions were 57% (P < 0.001), 96% (not significant (NS)), and 97% (NS) of that with water, respectively. Individuals tested in both studies (n = 9 of 12) had highly reproducible fexofenadine AUC with water (r(2) = 0.85, Po0.001) and extent of reduction of it with grapefruit juice (r(2) = 0.72, P < 0.01). Naringin most probably directly inhibited enteric OATP1A2 to decrease oral fexofenadine bioavailability. Inactivation of enteric CYP3A4 was probably not involved. Naringin appears to have sufficient safety, specificity, and sensitivity to be a clinical OATP1A2 inhibitor probe. Inherent OATP1A2 activity may be influenced by genetic factors. This appears to be the first report of a single dietary constituent clinically modulating drug transport.
引用
收藏
页码:495 / 502
页数:8
相关论文
共 45 条
[1]   Flavanone absorption after naringin, hesperidin, and citrus administration [J].
Ameer, B ;
Weintraub, RA ;
Johnson, JV ;
Yost, RA ;
Rouseff, RL .
CLINICAL PHARMACOLOGY & THERAPEUTICS, 1996, 60 (01) :34-40
[2]   GRAPEFRUIT JUICE FELODIPINE INTERACTION - MECHANISM, PREDICTABILITY, AND EFFECT OF NARINGIN [J].
BAILEY, DG ;
ARNOLD, JMO ;
MUNOZ, C ;
SPENCE, JD .
CLINICAL PHARMACOLOGY & THERAPEUTICS, 1993, 53 (06) :637-642
[3]   EFFECT OF GRAPEFRUIT JUICE AND NARINGIN ON NISOLDIPINE PHARMACOKINETICS [J].
BAILEY, DG ;
ARNOLD, JMO ;
STRONG, HA ;
MUNOZ, C ;
SPENCE, JD .
CLINICAL PHARMACOLOGY & THERAPEUTICS, 1993, 54 (06) :589-594
[4]   Grapefruit juice felodipine interaction:: Effect of naringin and 6′,7′-dihydroxybergamottin in humans [J].
Bailey, DG ;
Kreeft, JH ;
Munoz, C ;
Freeman, DJ ;
Bend, JR .
CLINICAL PHARMACOLOGY & THERAPEUTICS, 1998, 64 (03) :248-256
[5]   Grapefruit-felodipine interaction: Effect of unprocessed fruit and probable active ingredients [J].
Bailey, DG ;
Dresser, GR ;
Kreeft, JH ;
Munoz, C ;
Freeman, DJ ;
Bend, JR .
CLINICAL PHARMACOLOGY & THERAPEUTICS, 2000, 68 (05) :468-477
[6]  
Cvetkovic M, 1999, DRUG METAB DISPOS, V27, P866
[7]   Effect of grapefruit juice volume on the reduction of fexofenadine bioavailability: Possible role of organic anion transporting polypeptides [J].
Dresser, GK ;
Kim, RB ;
Bailey, DG .
CLINICAL PHARMACOLOGY & THERAPEUTICS, 2005, 77 (03) :170-177
[8]   Fruit juices inhibit organic anion transporting polypeptide-mediated drug uptake to decrease the oral availability of fexofenadine [J].
Dresser, GK ;
Bailey, DG ;
Leake, BF ;
Schwarz, UI ;
Dawson, PA ;
Freeman, DJ ;
Kim, RB .
CLINICAL PHARMACOLOGY & THERAPEUTICS, 2002, 71 (01) :11-20
[9]  
Edwards DJ, 1996, DRUG METAB DISPOS, V24, P1287
[10]   THE FATE OF NARINGIN IN HUMANS - A KEY TO GRAPEFRUIT JUICE DRUG-INTERACTIONS [J].
FUHR, U ;
KUMMERT, AL .
CLINICAL PHARMACOLOGY & THERAPEUTICS, 1995, 58 (04) :365-373